Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases

Abstract

Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.¹ report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.